Kura Oncology News - KURA

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
CHART Trader
Monthly Subscription
for only
$30.66
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Kura Oncology Inc KURA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 16.03 0.00 0.00 0.00 16.03 08:00:09
more quote information »

Recent News

Date Time Source Heading
9/16/201906:30GLOBEKura Oncology Doses First Patient in Phase 1 Clinical Trial..
9/03/201907:03EDGARCurrent Report Filing (8-k)
9/03/201906:30GLOBEKura Oncology Announces Positive Phase 2 Trial of Tipifarnib..
8/29/201906:30GLOBEKura Oncology to Participate in Two Upcoming Investor..
8/29/201905:00EDGARNotice of Effectiveness (effect)
8/28/201916:30EDGARProspectus Filed Pursuant to Rule 424(b)(3) (424b3)
8/21/201915:08EDGARSecurities Registration Statement (simplified Form) (s-3/a)
8/13/201917:18EDGARStatement of Changes in Beneficial Ownership (4)
8/13/201917:17EDGARInitial Statement of Beneficial Ownership (3)
8/12/201915:15EDGARCurrent Report Filing (8-k)
8/12/201915:05GLOBEKura Oncology Announces Appointment of Kathleen Ford as..
8/07/201906:30GLOBEKura Oncology to Present at Wedbush PacGrow Healthcare..
8/01/201915:38EDGARSecurities Registration Statement (simplified Form) (s-3)
8/01/201915:19EDGARQuarterly Report (10-q)
8/01/201915:08EDGARCurrent Report Filing (8-k)
8/01/201915:05GLOBEKura Oncology Reports Second Quarter 2019 Financial Results..
7/25/201906:30GLOBEKura Oncology to Report Second Quarter 2019 Financial..
7/24/201906:30GLOBEKura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan..
7/12/201915:05EDGARStatement of Changes in Beneficial Ownership (4)
7/11/201906:30GLOBEKura Oncology Expands Protection for Tipifarnib with New..
7/10/201913:59EDGARAmended Statement of Ownership (sc 13g/a)
6/27/201915:11EDGARStatement of Changes in Beneficial Ownership (4)
6/27/201915:10EDGARStatement of Changes in Beneficial Ownership (4)
6/27/201915:08EDGARStatement of Changes in Beneficial Ownership (4)
6/27/201915:07EDGARStatement of Changes in Beneficial Ownership (4)
6/27/201915:05EDGARStatement of Changes in Beneficial Ownership (4)
6/27/201915:02EDGARCurrent Report Filing (8-k)
6/21/201915:30GLOBEKura Oncology Announces Closing of Public Offering and Full..
6/19/201915:04EDGARCurrent Report Filing (8-k)
6/19/201915:03EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
6/18/201922:31GLOBEKura Oncology Announces Pricing of $100 Million Public..
6/18/201915:03EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
6/18/201915:01GLOBEKura Oncology Announces Commencement of Public Offering of..
6/14/201906:14EDGARCurrent Report Filing (8-k)
6/14/201906:00GLOBEKura Oncology Announces Positive Phase 2 Trial of Tipifarnib..
5/08/201907:00GLOBEKura Oncology to Present at Bank of America Merrill Lynch..
5/07/201915:22EDGARQuarterly Report (10-q)
5/07/201915:14EDGARCurrent Report Filing (8-k)
5/07/201915:05GLOBEKura Oncology Reports First Quarter 2019 Financial Results..
4/30/201906:30GLOBEKura Oncology to Report First Quarter 2019 Financial Results
4/29/201915:14EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
4/29/201915:02EDGARProxy Statement (definitive) (def 14a)
4/02/201915:04GLOBEKura Oncology Identifies Farnesylated Proteins Associated..
3/06/201906:30GLOBEKura Oncology to Participate in Two Upcoming Investor..
3/05/201915:43EDGARSecurities Registration: Employee Benefit Plan (s-8)
3/05/201915:23EDGARCurrent Report Filing (8-k)
3/05/201915:23EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
3/05/201915:17EDGARAnnual Report (10-k)
3/05/201915:06EDGARCurrent Report Filing (8-k)
3/05/201915:03GLOBEKura Oncology Reports Fourth Quarter and Full Year 2018..
See more news about this stock »
Your Recent History
NASDAQ
KURA
Kura Oncol..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190916 13:27:40